Market Research Logo

Global Autologous Cell Therapy Market 2017-2021

Global Autologous Cell Therapy Market 2017-2021

About Autologous Cell Therapy

Autologous cell therapy belongs to the field of regenerative medicine and is based on biologic cell-based therapies to cure various diseases, including those of oncology, neurology, and dermatology, to name a few. Autologous cell therapy is one of the fastest growing segments of regenerative medicine and hence, is attracting significant research funds from various quarters.

Technavio’s analysts forecast the global autologous cell therapy market to grow at a CAGR of 23.39% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global autologous cell therapy market for 2017-2021. To calculate the market size, the report considers the sales of autologous stem cell as well non-stem cell products.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Autologous Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Brainstorm Cell Therapeutics
  • Holostem Advanced Therapies
  • Osiris Therapeutics
  • Valeant
  • Vericel Corporation
Other prominent vendors
  • AbbVie
  • American CryoStem
  • AM-Pharma
  • Anterogen
  • apceth Biopharma
  • Astellas Pharma
  • Athersys
  • Baxter International
  • Beike Biotechnology
  • BIOTIME
  • bluebird bio
  • Bristol-Myers Squibb
  • Brainxell
  • Caladrius Biosciences
  • Cellular Biomedicine Group
  • Cellular Dynamics International (a subsidiary of Fujifilm)
  • Cesca Therapeutics
  • CHA Biotech
  • Chugai Pharmaceutical
  • Citospin
  • Corestem
  • Cytori Therapeutics
  • Daiichi Sankyo
  • Fujifilm
  • Gamida Cell
  • Global Stem Cells Group
  • Grupo Ferrer Internacional
  • GlaxoSmithKline
  • Hemostemix
  • Histocell
  • International Stem Cell
  • Ivy Institute of Stem Cells
  • Japan Regenerative Medicine
  • Kangstem Biotech
  • Kiadis Pharma
  • Laboratorios Salvat
  • MEDIPOST
  • Mesoblast
  • Nuo Therapeutics
  • Opsis Therapeutics
  • Pharmicell
  • Pluristem Therapeutics
  • Promethera Biosciences
  • Q Therapeutics
  • ReNeuron
  • RHEACELL
  • Salus Medical Solutions
  • Sangamo Therapeutics
  • Shire
  • Steminent Biotherapeutics
  • Sumitomo Dainippon Pharma
  • Taiwan Bio Therapeutics
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries
  • Thoratec Corporation
  • TiGenix
  • Translational Biosciences
  • TWO CELLS
  • U.S. Stem Cell
  • ViaCyte
  • VistaGen Therapeutics
Market driver
  • Increasing demand for effective drugs for cardiac and degenerative disorders
  • For a full, detailed list, view our report
Market challenge
  • Critical ethical challenges with respect to stem cell research
  • For a full, detailed list, view our report
Market trend
  • Private funding will fuel market growth
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Autologous Cell Therapy Market 2017-2021

Technavio recognizes the following companies as the key players in the global autologous cell therapy market: Brainstorm Cell Therapeutics, Holostem Advanced Therapies, Osiris Therapeutics, Valeant, and Vericel.

Other Prominent Vendors in the market are: AbbVie, American CryoStem, AM-Pharma, Anterogen, apceth Biopharma, Astellas Pharma, Athersys, Baxter International, Beike Biotechnology, BIOTIME, bluebird bio, Bristol-Myers Squibb, Brainxell, Caladrius Biosciences, Cellular Biomedicine, Cellular Dynamics International, Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, Citospin, Corestem, Cytori Therapeutics, Daiichi Sankyo, Fujifilm, Gamida Cell, Global Stem Cells, Grupo Ferrer Internacional, GlaxoSmithKline, Hemostemix, Histocell, International Stem Cell, Ivy Institute of Stem Cells, Japan Regenerative Medicine, Kangstem Biotech, Kiadis Pharma, Laboratorios Salvat, MEDIPOST, Mesoblast, Nuo Therapeutics, Opsis Therapeutics, Pharmicell, Pluristem Therapeutics, Promethera Biosciences, Q Therapeutics, ReNeuron, RHEACELL, Salus Medical Solutions, Sangamo Therapeutics, Shire, Steminent Biotherapeutics, Sumitomo Dainippon Pharma, Taiwan Bio Therapeutics, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Thoratec, TiGenix, Translational Biosciences, TWO CELLS, U.S. Stem Cell, ViaCyte, and VistaGen Therapeutics.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is private funding will fuel market growth. The increasing investments from private enterprises will likely change the market dynamics. Many vendors are investing in production or manufacturing facilities to improve their production or manufacturing expertise. They are also focusing on establishing new business units or companies to penetrate the market further.”

According to the report, one of the major drivers for this market is increasing demand for effective drugs for cardiac and degenerative disorders. There has been an increased demand for providing effective drugs for cardiac and degenerative disorders globally. Prior to the advent of autologous cell therapies, there was no effective drug to repair a damaged heart. The discovery of possible cardiac autologous cells opened new possibilities for repairing damaged cardiac tissue caused by acute myocardial infarction or coronary artery disease.

Further, the report states that one of the major factors hindering the growth of this market is critical ethical challenges with respect to stem cell research. Over the years, there has been a continuous debate over ethical issues related to stem cell therapy. Embryonic stem cell development is continuously debated upon by scientists and policy makers. The use of human embryonic stem cells in research has always concerned decision makers and the scientific fraternity. Some of the issues include the cloning of embryonic stem cells and the destruction of embryos to create cell lines.



Companies Mentioned

Brainstorm Cell Therapeutics, Holostem Advanced Therapies, Osiris Therapeutics, Valeant, Vericel, AbbVie, American CryoStem, AM-Pharma, Anterogen, apceth Biopharma, Astellas Pharma, Athersys, Baxter International, Beike Biotechnology, BIOTIME, bluebird bio, Bristol-Myers Squibb, Brainxell, Caladrius Biosciences, Cellular Biomedicine, Cellular Dynamics International, Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, Citospin, Corestem, Cytori Therapeutics, Daiichi Sankyo, Fujifilm, Gamida Cell, Global Stem Cells, Grupo Ferrer Internacional, GlaxoSmithKline, Hemostemix, Histocell, International Stem Cell, Ivy Institute of Stem Cells, Japan Regenerative Medicine, Kangstem Biotech, Kiadis Pharma, Laboratorios Salvat, MEDIPOST, Mesoblast, Nuo Therapeutics, Opsis Therapeutics, Pharmicell, Pluristem Therapeutics, Promethera Biosciences, Q Therapeutics, ReNeuron, RHEACELL, Salus Medical Solutions, Sangamo Therapeutics, Shire, Steminent Biotherapeutics, Sumitomo Dainippon Pharma, Taiwan Bio Therapeutics, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Thoratec, TiGenix, Translational Biosciences, TWO CELLS, U.S. Stem Cell, ViaCyte, and VistaGen Therapeutics.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Ethical issues faced by various institutes at different phases of research
  • Pipeline Landscape
    • Table Key Pipeline landscape
  • Market landscape
    • Market overview
      • Table Global autologous cell therapy market: Snapshot
      • Table Global autologous cell therapy market 2016-2021 ($ millions)
      • Table Global autologous cell therapy market: Opportunity analysis
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by application
    • Table Global autologous cell therapy market segmentation by application 2016
    • Oncology
      • Table Overview of oncology segment in global autologous cell therapy market
    • Musculoskeletal disorders
      • Table Overview of musculoskeletal disorders segment in global autologous cell therapy market
    • Dermatology
      • Table Overview of dermatology segment in global autologous cell therapy market
  • Market Segmentation by therapy
    • Table Global autologous cell therapy market segmentation by therapy 2016
    • Autologous stem cell therapy
      • Table Global autologous stem cell therapy market 2016-2021 ($ millions)
    • Autologous cellular immunotherapies
      • Table Global autologous cellular immunotherapies therapy market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of global autologous cell therapy market based on geography 2016 and 2021
    • Table Global autologous cell therapy market revenue by geography 2016-2021 ($ millions)
    • Autologous cell therapy market in Americas
      • Table Market scenario in Americas
      • Table Autologous cell therapy market in Americas 2016-2021 ($ millions)
    • Autologous cell therapy market in EMEA
      • Table Market scenario in EMEA
      • Table Autologous cell therapy market in EMEA 2016-2021 ($ millions)
    • Autologous cell therapy market in APAC
      • Table Market scenarios in APAC
      • Table Autologous cell therapy market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • Private funding will fuel market growth
    • Development of stem cell therapies by new regions
    • Increasing focus on development of drugs for emerging applications
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global stem cell therapy market 2016
      • Table Strategic success factors of companies in global autologous cell therapy market
  • Key vendor analysis
    • Brainstorm Cell Therapeutics
      • Table Brainstorm Cell Therapeutics: Key highlights
      • Table Brainstorm Cell Therapeutics: Strength assessment
      • Table Brainstorm Cell Therapeutics: Strategy assessment
      • Table Brainstorm Cell Therapeutics: Opportunity assessment
    • Holostem Advanced Therapies
      • Table Holostem Advanced Therapies: Key highlights
      • Table Holostem Advanced Therapies: Strength assessment
      • Table Holostem Advanced Therapies: Strategy assessment
      • Table Holostem Advanced Therapies: Opportunity assessment
    • Osiris Therapeutics
      • Table Osiris Therapeutics: Key highlights
      • Table Osiris Therapeutics: Strength assessment
      • Table Osiris Therapeutics: Strategy assessment
      • Table Osiris Therapeutics: Opportunity assessment
    • Valeant
      • Table Valeant: Key highlights
      • Table Valeant: Strength assessment
      • Table Valeant: Strategy assessment
      • Table Valeant: Opportunity assessment
    • Vericel Corporation
      • Table Vericel Corporation: Key highlights
      • Table Vericel Corporation: Strength assessment
      • Table Vericel Corporation: Strategy assessment
      • Table Vericel Corporation: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report